Synergetics Reports Second Quarter of Fiscal Year 2015 Results
O'FALLON, MO -- (Marketwired) -- 03/10/15 -- Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative surgical devices for ophthalmic and neurosurgical applications, today announced results for the second quarter of fiscal year 2015.
Second Quarter Summary:
- Total sales were $18.2 million, an increase of 20.5% year-over-year. Excluding the impacts of the acquisition of Sterimedix in the period, total sales increased 13.4% year-over-year.
- Ophthalmic sales increased 8.9% year-over-year and neurosurgery sales increased 36.4% year-over-year.
- Domestic sales increased 16.6% and International sales increased 31.0% year-over-year. International sales increased 36.8% year-over-year on a constant currency basis.
- Disposable product sales increased 18.0% and capital equipment sales increased 44.9%.
- GAAP EPS was $0.04 compared to a loss of $0.01 in the second quarter last year.
- Non-GAAP EPS was $0.07 compared to $0.00 in the second quarter last year.
- EBITDA increased 1,501.7% to $1.9 million, compared to $0.1 million last year.
"We are very pleased with our second quarter sales performance. We reported strong organic revenue growth of 13.4% year-over-year, and our total revenue growth exceeded 20% year-over-year including the partial-period contributions from our acquisition of Sterimedix Limited," said David M. Hable, the Company's President and Chief Executive Officer. "We continue to be encouraged by the progress we are making in the commercialization of the VersaVIT 2.0 system -- the largest organic growth driver of our ophthalmic business in the second quarter -- and our valuable relationships with our OEM customers continued to pay dividends this quarter as better-than-expected demand for our disposables and capital equipment drove strong sales growth compared to last year. Synergetics' performance over the first six-months of fiscal year 2015 has been very strong with sales up 13.7% year-over-year, operating profit up 132.1% and cash flow from operations of $4.8 million. We expect continued strength in our operating and financial results over the balance of fiscal 2015."
Second Quarter Results
Second quarter of fiscal 2015 sales totaled $18.2 million, an increase of 20.5%, compared to sales of $15.1 million in the second quarter of fiscal 2014. Total sales included contributions from our acquisition of Sterimedix Limited of $1.1 million, attributable to the period of December 10, 2014 to January 31, 2015. Second quarter sales performance was driven primarily by a 36.4% increase in Neurosurgery sales and an 8.9% increase in ophthalmic sales. Other sales increased 116.8% year-over-year.
Following the completion of the acquisition of Sterimedix, the Company assessed its sales presentation format and determined that a more comprehensive breakdown of its ophthalmic and neurosurgery sales is appropriate to more completely describe its revenues by market, as compared to reporting revenues by distribution category. The following table presents the Company's revised presentation of reporting enterprise-wide sales by market, as well as the previous presentation of reporting revenues by distribution category. The Company will provide sales results under both presentation formats for the balance of fiscal 2015 and will transition to the new presentation format of sales based upon market thereafter.
Three Three Six Six
Months Months Months Months
Ended Ended % Ended Ended %
January January Change January January Change
($'s in thousands) 31, 2015 31, 2014 y/y 31, 2015 31, 2014 y/y
-------- -------- ------ -------- -------- ------
Net Sales: Presentation based upon market
Ophthalmic (1) $ 9,985 $ 9,165 8.9% $ 19,510 $ 18,129 7.6%
Neurosurgery (2) 7,894 5,788 36.4% 14,912 12,245 21.8%
Other (3) 310 143 116.8% 414 252 64.3%
-------- -------- -------- --------
Total: $ 18,189 $ 15,096 20.5% $ 34,836 $ 30,626 13.7%
======== ======== ======== ========
Net Sales: Presentation based upon distribution
Ophthalmic(4) $ 8,228 $ 8,739 (5.8%) $ 16,958 $ 17,237 (1.6%)
OEM (5) 9,784 6,123 59.8% 17,470 12,971 34.7%
Other (6) 177 234 (24.4%) 408 418 (2.4%)
-------- -------- -------- --------
Total: $ 18,189 $ 15,096 20.5% $ 34,836 $ 30,626 13.7%
======== ======== ======== ========
- Total ophthalmic sales increased 8.9% to $10.0 million, compared to $9.2 million in the second quarter of fiscal 2014. Domestic ophthalmic sales decreased 5.0% primarily due to declines in our base ophthalmic business offset, partially, by sales of VersaVIT" and procedural kits. International ophthalmic sales increased 27.2% year-over-year primarily due to the addition of Sterimedix sales from December 10, 2014 through January 31, 2015, partially offset by a 4.3% decrease in international ophthalmology direct and distributor sales, primarily due to foreign currency adjustments.
- Total neurosurgery sales increased 36.4% to $7.9 million, compared to $5.8 million in the second quarter of fiscal 2014. The increase in neurosurgery sales benefited primarily from strong volumes of disposable products and generators sold to Codman and Stryker compared to last year. Other sales increased 116.8% to $310,000, compared to $143,000 last year, primarily due to the addition of Sterimedix aesthetics sales from December 10, 2014 through January 31, 2015.
- Total domestic sales increased 16.6% to $12.9 million in the second quarter of fiscal 2015, driven by higher neurosurgery sales, which are recorded as Domestic sales, partially offset by a 5.0% decline in domestic ophthalmic sales compared to last year. International sales increased 31.0% to $5.3 million primarily due to the addition of Sterimedix sales December 10, 2014 through January 31, 2015, partially offset by the 4.3% decrease in international ophthalmology sales related to the impacts of foreign currency exchange in the period.
- Capital equipment sales increased 44.9% to $2.3 million, or 12.9% of sales in the second quarter of fiscal 2015 compared to $1.6 million, or 10.7% of sales, in the second quarter of fiscal 2014. Disposable product sales increased 18.0% to $15.5 million, or 85.4% of sales this year, compared to sales of $13.2 million, or 87.2% of sales in the second quarter of fiscal 2014.
Gross profit for the second quarter of fiscal 2015 totaled $9.6 million, or 52.7% of sales, compared to $8.4 million, or 55.6% of sales, in the second quarter of fiscal 2014. Year-over-year gross margin performance was driven by a product mix shift to neurosurgical sales from ophthalmic sales compared to last year, costs related to our final production at the King of Prussia facility, foreign currency exchange and inventory purchase price allocation related to our acquisition of Sterimedix.
Total operating expenses decreased 4.4% year-over-year to $8.4 million, or 46.1% of sales, in the second quarter of fiscal 2015 from $8.8 million, or 58.1% of sales, in the comparable 2014 period. Research and development expenses decreased 32.1% to $1.0 million, or 5.7% of sales, compared to 10.0% of sales last year. Sales and marketing expenses increased 0.4% to $3.6 million, or 20.0% of sales, compared to 24.0% of sales last year. General and administrative expenses decreased 2.0% to $2.9 million, or 16.2% of sales, compared to 19.9% of sales last year. Total operating expenses also increased due to higher expenses related to the Company's closure of its King of Prussia facility compared to the prior year period.
Reported operating income for the second quarter of fiscal 2015 increased $1.6 million to $1.2 million, or 6.6% of sales, compared to an operating loss of $0.4 million last year. Reported net income increased $1.2 million to approximately $1.0 million, or $0.04 per diluted share, compared to a loss of $0.2 million, or $0.01 per diluted share, for the same period of fiscal 2014.
As of January 31, 2015, the Company had approximately $8.9 million in cash and $2.75 million in interest-bearing debt. Cash flows provided by operating activities were $4.8 million for the six months ended January 31, 2015, compared to cash flows used by operating activities of $302,000 for the comparable fiscal 2014 period.
Conference Call Information
Synergetics USA, Inc. will host a conference call on Tuesday, March 10, 2015 at 4:00 p.m. Central Time (5:00 p.m. Eastern) to review the Company's results for the fiscal second quarter ended January 31, 2015. The toll free dial-in number to participate live on this call is (800) 588-4973, confirmation code 39067049. For callers outside the U.S., the number is (847) 230-5643. The conference call will also be available live via webcast at http://www.synergeticsusa.com. A replay will be available on the Company's website for approximately 30 days.
Notes to Accompany the Enterprise-wide Sales Table:
(1) Net sales from ophthalmic represent all sales of ophthalmic devices from direct sales representatives, distribution partners and OEMs. Recognition of deferred revenue of $322,000 and $644,000 from Alcon, Inc. is included in this category for the three and six months ended January 31, 2015 and 2014, respectively.
(2) Net sales from neurosurgery represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and certain neurosurgery disposables sold through distribution. Many of the products that the Company sells to its neurosurgery OEM customers are shipped to their non-U.S. customers in various countries around the world, but are included in the Company's domestic revenues.
(3) Other net sales represent all sales of aesthetic devices, freight and other miscellaneous revenues.
(4) Net sales from ophthalmic represent sales of ophthalmic devices from direct sales representatives and distribution partners.
(5) Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products. Recognition of deferred revenues of $322,000 and $644,000 from Alcon, Inc. is included in this category for the three and six months ended January 31, 2015 and 2014, respectively. Many of the products that the Company sells to its neurosurgery OEM customers are shipped to their non-U.S. customers in various countries around the world, but are included in the Company's domestic revenues.
(6) Other net sales represent direct neurosurgery revenues and other miscellaneous revenues.
About Synergetics USA, Inc.
Through continuous improvement and development of our people, our mission is to design, manufacture and market innovative surgical devices, capital equipment, accessories and disposables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients.
Synergetics USA, Inc. (the "Company") is a leading supplier of precision surgical devices. The Company's primary focus is on the disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent sales distributor organizations, both domestically and internationally, and important strategic alliances with market leaders. The Company's product lines focus on precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company's website address is http://www.synergeticsusa.com.
Use of Non-GAAP Financial Information
The Company measures its performance primarily through its growth in revenue and operating profit. In addition to results reported in accordance with GAAP, the Company provides adjusted operating income and margin, EBITDA and adjusted diluted earnings per share. These adjusted amounts consist of GAAP amounts excluding the adjustment for exit costs occurring during the period. Adjusted earnings per diluted share were calculated by dividing adjusted net income for diluted earnings per share by diluted weighted average shares outstanding. The Company believes that the presentation of adjusted operating income and margin, EBITDA and adjusted diluted earnings per share provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.
These non-GAAP measures are considered by the Company's Board of Directors and management as a basis for measuring and evaluating the Company's overall operating performance and ability to service debt. They are presented to enhance an understanding of the Company's operating results and are not intended to represent cash flow or results of operations.
These non-GAAP measures are not in accordance with, or an alternative to, measures prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.
Forward-Looking Statements
Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the year ended July 31, 2014 as updated from time to time in our filings with the Securities and Exchange Commission. The Company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.
Synergetics USA, Inc. and Subsidiaries
Condensed Consolidated Statements of Income and Comprehensive (Loss) Income
(Unaudited)
Three and Six Months Ended January 31, 2015 and 2014
(Dollars in thousands, except share and per share data)
Three Three
Months Months Six Months Six Months
Ended Ended Ended Ended
January 31, January 31, January 31, January 31,
2015 2014 2015 2014
----------- ----------- ----------- ------------
Net sales $ 18,189 $ 15,096 $ 34,836 $ 30,626
Cost of sales 8,605 6,698 15,982 13,304
----------- ----------- ----------- ------------
Gross profit 9,584 8,398 18,854 17,322
----------- ----------- ----------- ------------
Operating expenses
Research and
development 1,028 1,513 2,227 2,710
Sales and marketing 3,643 3,630 7,339 7,205
Medical device excise
tax 116 115 244 240
Exit costs 657 514 719 514
General and
administrative 2,942 3,003 5,970 5,638
----------- ----------- ----------- ------------
8,386 8,775 16,499 16,307
----------- ----------- ----------- ------------
Operating income
(loss) 1,198 (377) 2,355 1,015
----------- ----------- ----------- ------------
Other income (expense)
Investment income 1 3 2 6
Interest expense (14) -- (14) --
----------- ----------- ----------- ------------
(13) 3 (12) 6
----------- ----------- ----------- ------------
Income (loss) from
operations before
provision (benefit)
for income taxes 1,185 (374) 2,343 1,021
Provision (benefit) for
income taxes 233 (149) 623 312
----------- ----------- ----------- ------------
Net income (loss) $ 952 $ (225) $ 1,720 $ 709
=========== =========== =========== ============
Earnings (loss) per
share:
Basic earnings (loss)
per share $ 0.04 $ (0.01) $ 0.07 $ 0.03
=========== =========== =========== ============
Diluted earnings (loss)
per share $ 0.04 $ (0.01) $ 0.07 $ 0.03
=========== =========== =========== ============
Basic weighted average
common shares
outstanding 25,364,574 25,309,641 25,352,279 25,301,830
Diluted weighted
average common shares
outstanding 25,424,835 25,309,641 25,407,508 25,386,679
Net income (loss) $ 952 $ (225) $ 1,720 $ 709
Foreign currency
translation adjustment (1,311) (35) (1,816) 140
----------- ----------- ----------- ------------
Comprehensive (loss)
income $ (359) $ (260) $ (96) $ 849
=========== =========== =========== ============
SYNERGETICS USA, INC. AND SUBSIDIARIES
Unaudited Table of Net Income and EBITDA
Three and Six Months Ended January 31, 2015 and 2014
(In thousands)
Three Months Three Months
Ended Ended
January 31, January 31,
EBITDA Reconciliation 2015 2014
------------- ------------
Net income (loss) $ 952 $ (225)
Interest expense 14 --
Income tax provision (benefit) 233 (149)
Depreciation 380 305
Amortization 295 186
------------- ------------
EBITDA $ 1,874 $ 117
============= ============
Six Months Six Months
Ended Ended
January 31, January 31,
EBITDA Reconciliation 2015 2014
------------- -------------
Net income $ 1,720 $ 709
Interest 14 --
Income tax provision 623 312
Depreciation 689 571
Amortization 543 366
------------- -------------
EBITDA $ 3,589 $ 1,958
============= =============
SYNERGETICS USA, INC. AND SUBSIDIARIES
Unaudited Table of Adjusted Operating Income, Operating Margin and Non-GAAP
EPS
Three and Six Months Ended January 31, 2015 and 2014
(Dollars in thousands, except per share and per share data)
Three Three
Months Months Six Months Six Months
Ended Ended Ended Ended
Adjusted Operating January 31, January 31, January 31, January 31,
Income 2015 2014 2015 2014
----------- ----------- ----------- -----------
GAAP Operating Income
(Loss) $ 1,198 $ (377) $ 2,355 $ 1,015
Exit costs 657 514 719 514
Sterimedix acquisition
related costs (1) 204 -- 290 --
----------- ----------- ----------- -----------
Adjusted operating
income 2,059 137 3,364 1,529
Sales 18,189 15,096 34,836 30,626
Adjusted operating
margin 11.3% 0.9% 9.7% 5.0%
----------- ----------- ----------- -----------
Non-GAAP EPS Impact
Exit costs $ 657 $ 514 $ 719 $ 514
Sterimedix acquisition
related costs (1) 204 -- 290 --
----------- ----------- ----------- -----------
Total 861 514 1,009 514
----------- ----------- ----------- -----------
Effective tax rate 19.7 39.8 26.6 30.6
----------- ----------- ----------- -----------
Tax effected costs 691 309 741 357
Diluted weighted average
common shares 25,424,835 25,309,641 25,407,508 25,386,679
----------- ----------- ----------- -----------
Diluted earnings per
share $ 0.03 $ 0.01 $ 0.03 $ 0.01
=========== =========== =========== ===========
(1) Included in the general and administrative expense line item.
Synergetics USA, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
As of January 31, 2015 (Unaudited) and July 31, 2014
(Dollars in thousands, except share data)
January 31, July 31,
2015 2014
------------ ------------
Assets
Current assets
Cash and cash equivalents $ 8,866 $ 15,443
Accounts receivable, net of allowance for
doubtful accounts of $646 and $722,
respectively 13,188 14,641
Inventories 16,537 15,134
Prepaid expenses 1,075 1,223
Deferred income taxes 2,233 2,042
------------ ------------
Total current assets 41,899 48,483
Property and equipment, net 10,337 8,785
Intangible and other assets
Goodwill 17,429 12,738
Other intangible assets, net 19,574 11,911
Deferred income taxes -- 1,219
Patents, net 1,415 1,472
Deferred financing costs, net 122 --
Cash value of life insurance 107 107
------------ ------------
Total assets $ 90,833 $ 84,715
============ ============
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 3,672 $ 2,530
Accrued expenses 2,788 2,845
Income taxes payable 405 386
Contingent acquisition liability 561 --
Current maturities of long-term debt 550 --
Deferred revenue 1,288 1,288
------------ ------------
Total current liabilities 9,264 7,049
------------ ------------
Long-Term liabilities
Borrowings under term loan facility 2,200 --
Deferred income taxes 130 --
Contingent acquisition liability 2,000 --
Deferred revenue 12,598 13,242
------------ ------------
Total long-term liabilities 16,928 13,242
------------ ------------
Total liabilities 26,192 20,291
------------ ------------
Commitments and contingencies
Stockholders' equity
Common stock at January 31, 2015 and July 31,
2014, $0.001 par value, 50,000,000 shares
authorized; 25,566,332 and 25,364,608 shares
issued and outstanding, respectively 26 25
Additional paid-in capital 28,956 28,594
Retained earnings 37,880 36,160
Accumulated other comprehensive loss:
Foreign currency translation adjustment (2,171) (355)
------------ ------------
Total stockholders' equity 64,691 64,424
------------ ------------
Total liabilities and stockholders' equity $ 90,833 $ 84,715
============ ============
Synergetics USA Inc. and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)
Six Months Ended January 31, 2015 and 2014
(Dollars in thousands)
Six Months Six Months
Ended Ended
January 31, January 31,
2015 2014
------------ ------------
Cash Flows from Operating Activities
Net income $ 1,720 $ 709
Adjustments to reconcile net income to net
cash provided by (used in) operating
activities
Depreciation 689 571
Amortization 543 366
Provision for doubtful accounts receivable 8 6
Stock-based compensation 388 605
Deferred income taxes (67) (35)
Changes in assets and liabilities
Decrease (increase) in:
Accounts receivable 1,638 1,164
Inventories (36) (1,854)
Prepaid expenses 177 (254)
Income taxes refundable -- 254
Increase (decrease) in:
Accounts payable 730 (213)
Accrued expenses (243) (940)
Deferred revenue (644) (644)
Income taxes payable (120) (37)
------------ ------------
Net cash provided by (used in) operating
activities 4,783 (302)
------------ ------------
Cash Flows from Investing Activities
Purchase of property and equipment (393) (735)
Acquisition of Sterimedix (13,177) --
Acquisition of patents and other intangibles (69) (139)
------------ ------------
Net cash used in investing activities (13,639) (874)
------------ ------------
Cash Flows from Financing Activities
Deferred financing costs (123) --
Proceeds from borrowings under the Revolving
Credit Line 2,750 --
Proceeds from the issuance of common stock 28 36
Tax benefit associated with the exercise of
non-qualified stock options 16 25
------------ ------------
Net cash provided by financing activities 2,671 61
------------ ------------
Foreign exchange rate effect on cash and cash
equivalents (392) (133)
------------ ------------
Net decrease in cash and cash equivalents (6,577) (1,248)
Cash and cash equivalents
Beginning 15,443 12,470
------------ ------------
Ending $ 8,866 $ 11,222
============ ============
SYNERGETICS USA, INC. 3845 Corporate Centre Drive O'Fallon, Missouri 63368 (636) 939-5100 http://www.synergeticsusa.com Pamela G. Boone Chief Financial Officer
Source: Synergetics USA, Inc.